Artigos de revistas sobre o tema "Drug-sparing regimen"
Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos
Veja os 50 melhores artigos de revistas para estudos sobre o assunto "Drug-sparing regimen".
Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.
Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.
Veja os artigos de revistas das mais diversas áreas científicas e compile uma bibliografia correta.
Rosa, Rossana, Jose F. Suarez, Marco A. Lorio, Michele I. Morris, Lilian M. Abbo, Jacques Simkins, Giselle Guerra et al. "Impact of antiretroviral therapy on clinical outcomes in HIV+ kidney transplant recipients: Review of 58 cases". F1000Research 5 (21 de dezembro de 2016): 2893. http://dx.doi.org/10.12688/f1000research.10414.1.
Texto completo da fonteDutta, Noton K., Abdullah Alsultan, Thomas J. Gniadek, Deborah A. Belchis, Michael L. Pinn, Khisimuzi E. Mdluli, Eric L. Nuermberger, Charles A. Peloquin e Petros C. Karakousis. "Potent Rifamycin-Sparing Regimen Cures Guinea Pig Tuberculosis as Rapidly as the Standard Regimen". Antimicrobial Agents and Chemotherapy 57, n.º 8 (3 de junho de 2013): 3910–16. http://dx.doi.org/10.1128/aac.00761-13.
Texto completo da fonteRuzicka, Daniel J., Mayuko Kamakura, Naho Kuroishi, Nobuyuki Oshima, Miyuki Yamatani, Jingbo Yi, Bruce Crawford, Kunihisa Tsukada e Shinichi Oka. "Characteristics of 2-drug regimen users living with HIV-1 in a real-world setting: A large-scale medical claim database analysis in Japan". PLOS ONE 17, n.º 6 (14 de junho de 2022): e0269779. http://dx.doi.org/10.1371/journal.pone.0269779.
Texto completo da fonteMaggiolo, Franco, Nicola Gianotti, Laura Comi, Elisa Di Filippo, Laura Fumagalli, Silvia Nozza, Laura Galli, Daniela Valenti, Marco Rizzi e Antonella Castagna. "Rilpivirine plus cobicistat-boosted darunavir as alternative to standard three-drug therapy in HIV-infected, virologically suppressed subjects: Final results of the PROBE 2 trial". Antiviral Therapy 26, n.º 3-5 (maio de 2021): 51–57. http://dx.doi.org/10.1177/13596535211042226.
Texto completo da fonteSleeper, Rebecca B. "Antipsychotic Dose-Sparing Effect with Addition of Memantine". Annals of Pharmacotherapy 39, n.º 9 (setembro de 2005): 1573–76. http://dx.doi.org/10.1345/aph.1g207.
Texto completo da fonteTiberi, Simon, Marie-Christine Payen, Giovanni Sotgiu, Lia D'Ambrosio, Valentina Alarcon Guizado, Jan Willem Alffenaar, Marcos Abdo Arbex et al. "Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB". European Respiratory Journal 47, n.º 4 (10 de março de 2016): 1235–43. http://dx.doi.org/10.1183/13993003.02146-2015.
Texto completo da fonteFischl, Margaret A., Ann C. Collier, A. Lisa Mukherjee, Judith E. Feinberg, Lisa M. Demeter, Pablo Tebas, Marina Giuliano et al. "Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen". AIDS 21, n.º 3 (janeiro de 2007): 325–33. http://dx.doi.org/10.1097/qad.0b013e328011ddfa.
Texto completo da fonteKaroney, Mercy Jelagat, Mathew Kirtptonui Koech, Evangeline Wawira Njiru e Willis Dixon Owino Ong’or. "Proximal tubular renal dysfunction among HIV infected patients on Tenofovir versus Tenofovir sparing regimen in western Kenya". PLOS ONE 17, n.º 9 (15 de setembro de 2022): e0273183. http://dx.doi.org/10.1371/journal.pone.0273183.
Texto completo da fonteStürmer, Martin, Schlomo Staszewski e Hans Wilhelm Doerr. "Quadruple Nucleoside Therapy with Zidovudine, Lamivudine, Abacavir and Tenofovir in the Treatment of HIV". Antiviral Therapy 12, n.º 5 (julho de 2007): 695–704. http://dx.doi.org/10.1177/135965350701200514.
Texto completo da fonteKovalskaya, Galina N., Dina Y. Zhukova e Ekaterina N. Mikhalevich. "Interaction of Drugs Used for the Treatment of Cardiovascular Diseases". Acta Biomedica Scientifica 4, n.º 1 (4 de abril de 2019): 36–42. http://dx.doi.org/10.29413/abs.2019-4.1.6.
Texto completo da fonteDwyer, Dominic E., Cassy Workman, Gillian Hales, Janaki Amin, David Cooper, John Miller e Sean Emery. "Enfuvirtide in HIV-1-Infected Individuals Changing Therapy to A Nucleoside Reverse Transcriptase Inhibitor Sparing Regimen: The Alliance Study". Antiviral Therapy 11, n.º 4 (1 de maio de 2005): 409–19. http://dx.doi.org/10.1177/135965350601100406.
Texto completo da fonteRabin, Bradford C., Kristina Reid, Tian-Zhi Guo, Eva Gustafsson, Chousheng Zhang e Mervyn Maze. "Sympatholytic and Minimum Anesthetic Concentration-sparing Responses are Preserved in Rats Rendered Tolerant to the Hypnotic and Analgesic Action of Dexmedetomidine, a Selective α2-adrenergic Agonist". Anesthesiology 85, n.º 3 (1 de setembro de 1996): 565–73. http://dx.doi.org/10.1097/00000542-199609000-00016.
Texto completo da fonteLewis, David A. "New treatment options for Neisseria gonorrhoeae in the era of emerging antimicrobial resistance". Sexual Health 16, n.º 5 (2019): 449. http://dx.doi.org/10.1071/sh19034.
Texto completo da fonteAutar, Reshma S., Mark A. Boyd, Ferdinand WMN Wit, Kiat Ruxrungtham, Jongkol Sankote, Joep MA Lange, David A. Cooper, Praphan Phanuphak, David M. Burger e Peter Reiss. "Relationships between Drug Exposure, Changes in Metabolic Parameters and Body Fat in HIV-Infected Patients Switched to a Nucleoside Sparing Regimen". Antiviral Therapy 12, n.º 8 (novembro de 2007): 1265–72. http://dx.doi.org/10.1177/135965350701200813.
Texto completo da fonteBrugière, Olivier, Alexandre Vallée, Quentin Raimbourg, Marie-Noelle Peraldi, Sylvie Colin de Verdière, Laurence Beaumont, Abdulmonem Hamid et al. "Conversion to belatacept after lung transplantation: Report of 10 cases". PLOS ONE 18, n.º 3 (15 de março de 2023): e0281492. http://dx.doi.org/10.1371/journal.pone.0281492.
Texto completo da fonteSultan, Mamoona, Adeena Khan, Syed Shahid Habib e Dheyab Abdulsalam. "Unique clinical spectrum with distinguishing diagnostic features in Vogt-Koyanagi-Harada syndrome". BMJ Case Reports 12, n.º 12 (dezembro de 2019): e231397. http://dx.doi.org/10.1136/bcr-2019-231397.
Texto completo da fonteDelyagin, Wassili M., e Inna V. Lukjanova. "Heart failure in children and adolescents (high yield topics for primary care pediatrician)". Pediatrics. Consilium Medicum, n.º 3 (15 de setembro de 2021): 277–84. http://dx.doi.org/10.26442/26586630.2021.3.200998.
Texto completo da fonteHong, H., D. W. Dowdy, K. E. Dooley, H. W. Francis, C. Budhathoki, H.-R. Han e J. E. Farley. "Risk of hearing loss among multidrug-resistant tuberculosis patients according to cumulative aminoglycoside dose". International Journal of Tuberculosis and Lung Disease 24, n.º 1 (1 de janeiro de 2020): 65–72. http://dx.doi.org/10.5588/ijtld.19.0062.
Texto completo da fonteKast, Richard E., Marc-Eric Halatsch e Rafael Rosell. "OPALS: A New Osimertinib Adjunctive Treatment of Lung Adenocarcinoma or Glioblastoma Using Five Repurposed Drugs". Cells 10, n.º 5 (10 de maio de 2021): 1148. http://dx.doi.org/10.3390/cells10051148.
Texto completo da fonteTotiger, Tulasigeri M., Anirban Ghoshal, Jenna Zabroski, Anya Sondhi, Saanvi Bucha, Jacob Jahn, Yangbo Feng e Justin Taylor. "Targeted Therapy Development in Acute Myeloid Leukemia". Biomedicines 11, n.º 2 (20 de fevereiro de 2023): 641. http://dx.doi.org/10.3390/biomedicines11020641.
Texto completo da fonteEisbruch, Avraham, John M. Robertson, Carolyn M. Johnston, Joseph Tworek, Kevin R. Reynolds, James A. Roberts e Theodore S. Lawrence. "Bromodeoxyuridine Alternating With Radiation for Advanced Uterine Cervix Cancer: A Phase I and Drug Incorporation Study". Journal of Clinical Oncology 17, n.º 1 (janeiro de 1999): 31. http://dx.doi.org/10.1200/jco.1999.17.1.31.
Texto completo da fonteKim, You Sun. "Treatment of inflammatory bowel diseases: focusing on 5-aminosalicylates and immunomodulators". Journal of the Korean Medical Association 64, n.º 9 (10 de setembro de 2021): 596–604. http://dx.doi.org/10.5124/jkma.2021.64.9.596.
Texto completo da fonteSher, Taimur, Kena C. Miller, Sikander Ailawadhi, Debbie Manfredi, Margaret Wood, Wei Tan, Gregory Wilding et al. "Bortezomib in Combination with Pegylated Liposomal Doxorubicin and Thalidomide (VDT), An Effective Steroid Independent Regimen for Previously Untreated Multiple Myeloma Patients: Final Result of a Phase II Study." Blood 114, n.º 22 (20 de novembro de 2009): 618. http://dx.doi.org/10.1182/blood.v114.22.618.618.
Texto completo da fonteLaw, Lisa Y., Ryan Stevenson, Gwendolyn Ho, Bijay Nair, Asakura Laura e Antoine Sayegh. "Venetoclax-Based Regimen for Treatment of Patients with Acute Myeloid Leukemia in Community Based Practices". Blood 134, Supplement_1 (13 de novembro de 2019): 5081. http://dx.doi.org/10.1182/blood-2019-121816.
Texto completo da fonteHorvath, Lena, e Andreas Pircher. "ASCO 2020 non-small lung cancer (NSCLC) personal highlights". memo - Magazine of European Medical Oncology 14, n.º 1 (13 de janeiro de 2021): 66–69. http://dx.doi.org/10.1007/s12254-020-00673-2.
Texto completo da fonteFinn, Jonathan D., Patricia Favaro, J. Fraser Wright, Federico Mingozzi, Katherine A. High e Valder R. Arruda. "Rabbit Anti-Thymocyte Globulin (rATG) Administrated Concomitantly with Liver Delivery of AAV2-hFIX Can Promote Inhibitor Formation In Rhesus Macaques." Blood 116, n.º 21 (19 de novembro de 2010): 3765. http://dx.doi.org/10.1182/blood.v116.21.3765.3765.
Texto completo da fonteDybkær, Karen, Hanne Due, Rasmus Froberg Brøndum, Ken H. Young e Martin Bøgsted. "Addition of Drug-Response Specific Micro-RNAs to the International Prognostic Index Improves Prognostic Stratification of GCB-DLBCL Patients Treated with R-CHOP". Blood 134, Supplement_1 (13 de novembro de 2019): 1623. http://dx.doi.org/10.1182/blood-2019-122351.
Texto completo da fonteSoon, Gaik H., Ping Shen, Eu-Leong Yong, Paul Pham, Charles Flexner e Lawrence Lee. "Pharmacokinetics of Darunavir at 900 Milligrams and Ritonavir at 100 Milligrams Once Daily when Coadministered with Efavirenz at 600 Milligrams Once Daily in Healthy Volunteers". Antimicrobial Agents and Chemotherapy 54, n.º 7 (12 de abril de 2010): 2775–80. http://dx.doi.org/10.1128/aac.01564-09.
Texto completo da fonteNg, Loke, Yeo, Chng e Tan. "A Meta-Analysis of the Utility of Preoperative Intravenous Paracetamol for Post-Caesarean Analgesia". Medicina 55, n.º 8 (31 de julho de 2019): 424. http://dx.doi.org/10.3390/medicina55080424.
Texto completo da fonteJeny, Florence, Hilario Nunes e Dominique Valeyre. "Current Medical Therapy for Sarcoidosis". Seminars in Respiratory and Critical Care Medicine 38, n.º 04 (27 de julho de 2017): 523–31. http://dx.doi.org/10.1055/s-0037-1604032.
Texto completo da fonteS., Sivakumar, e Banupriya K. "Monitoring of adverse drug reactions caused by methotrexate at the dermatology department of a tertiary care centre". International Journal of Research in Dermatology 3, n.º 3 (24 de agosto de 2017): 389. http://dx.doi.org/10.18203/issn.2455-4529.intjresdermatol20173078.
Texto completo da fonteLauretti, Gabriela R., Izabel C. P. R. Lima, Marlene P. Reis, Wiliam A. Prado e Newton L. Pereira. "Oral Ketamine and Transdermal Nitroglycerin as Analgesic Adjuvants to Oral Morphine Therapy for Cancer Pain Management". Anesthesiology 90, n.º 6 (1 de junho de 1999): 1528–33. http://dx.doi.org/10.1097/00000542-199906000-00005.
Texto completo da fonteGandola, L., M. Nantron, A. Marchianò, A. Pession, P. Indolfi, A. Di Cataldo, P. Collini, G. Arcamone, F. Fossati Bellani e F. Spreafico. "Outcome in stage IV Wilms tumor treated according to the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) trials". Journal of Clinical Oncology 27, n.º 15_suppl (20 de maio de 2009): 10031. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.10031.
Texto completo da fonteMironov, S. P., M. B. Cykunov, G. M. Burmakova e S. V. Andreev. "Lumbosacral pain in athletes and ballet dancers: spondylolysis and spondylolisthesis. Conservative treatment". N.N. Priorov Journal of Traumatology and Orthopedics 27, n.º 1 (1 de abril de 2020): 11–18. http://dx.doi.org/10.17816/vto202027111-18.
Texto completo da fontePei, Xin-Yan, Michael W. Sanderson, Leena E. Youssefian, Jessica Felthousen, Lora B. Kramer, Yun Dai e Steven Grant. "Bcl-2 Antagonism Potentiates MEK1/2/Chk1 Inhibitor Lethality in Multiple Myeloma Cells Overexpressing Bcl-2 through a Stat3-Dependent Mechanism". Blood 124, n.º 21 (6 de dezembro de 2014): 4763. http://dx.doi.org/10.1182/blood.v124.21.4763.4763.
Texto completo da fonteWinkler, K., G. Beron, G. Delling, U. Heise, H. Kabisch, C. Purfürst, J. Berger, J. Ritter, H. Jürgens e V. Gerein. "Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response." Journal of Clinical Oncology 6, n.º 2 (fevereiro de 1988): 329–37. http://dx.doi.org/10.1200/jco.1988.6.2.329.
Texto completo da fontevan der Lee, Miranda M. C., Tanja van Achterberg, Kaylee Hersmus, Annet Brouwers-Vos, Monique van der Vleuten, Maurien Pruis, Wendy Kappers et al. "Abstract 3129: BYON4413, an in vivo active CD123-targeting antibody-drug conjugate, combines effectively with azacitidine and venetoclax in acute myeloid leukemia cell lines". Cancer Research 84, n.º 6_Supplement (22 de março de 2024): 3129. http://dx.doi.org/10.1158/1538-7445.am2024-3129.
Texto completo da fonteNormant, Emmanuel, Marcelo Lima Ribeiro, Nuria Profitos-Peleja, Pedro Blecua, Diana Reyes-Garau, Juliana Carvalho Santos, Marc Armengol, Miranda Fernández-Serrano, Hari P. Miskin e Gael Roue. "The Ublituximab-Umbralisib (U2) Drug Regimen Potentiates the Activity of the Novel CD47-CD19 Bispecific Antibody, TG-1801, through the Activation of the G Protein-Coupled Receptor EBI2/GPR183". Blood 138, Supplement 1 (5 de novembro de 2021): 1196. http://dx.doi.org/10.1182/blood-2021-150570.
Texto completo da fonteLiguori, Nicholas R., Ashley Fss Uruchurtu, Young Lee, Leiqing Zhang, Abbas Abbas, Varun Prabhu, Lanlan Zhou, Christopher J. Azzoli e Wafik S. El-Deiry. "Abstract 4064: Synergistic activity of Lurbinectidin plus ONC201 in SCLC is associated with ATF4, CHOP and pChk1 induction". Cancer Research 82, n.º 12_Supplement (15 de junho de 2022): 4064. http://dx.doi.org/10.1158/1538-7445.am2022-4064.
Texto completo da fonteLu, Norman, Patricia Soulard, Kay Li, Heather Sadlish, Chris Yates, Xiubin Gu, Ibrahim Kays et al. "Abstract 3306: RGT-M001, a first-in-class small molecule mRNA degrader of the oncogenic transcription factor c-Myb, demonstrated remarkable single agent anti-tumor efficacy in cancer patient-derived xenograft model". Cancer Research 84, n.º 6_Supplement (22 de março de 2024): 3306. http://dx.doi.org/10.1158/1538-7445.am2024-3306.
Texto completo da fonteDeisher, Theresa, Margaret Taylor, Arya Ashok, Peter Jarzyna, Yumna Zahid, Stephanie Lee-Diaz, Colleen Rylatt, Kendra Poulin e Vaishnavi Parthasarathy. "AVM0703, a New Treatment Option for Lymphoma Patients". Blood 134, Supplement_1 (13 de novembro de 2019): 5308. http://dx.doi.org/10.1182/blood-2019-128812.
Texto completo da fonteHamilton, Erika Paige, Manish R. Patel, Jordi Rodon, David S. Hong, Alison M. Schram, Pasi A. Janne, Patricia LoRusso et al. "Masterkey-01: Phase I/II, open-label multicenter study to assess safety, tolerability, pharmacokinetics, and antitumor activity of BDTX-189, an inhibitor of allosteric ErbB mutations, in patients with advanced solid malignancies." Journal of Clinical Oncology 38, n.º 15_suppl (20 de maio de 2020): TPS3665. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.tps3665.
Texto completo da fontediCapua Siegel, David Samuel, Thomas Martin, Michael Wang, Ravi Vij, Andrzej J. Jakubowiak, Sundar Jagannath, Sagar Lonial et al. "Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM)". Blood 116, n.º 21 (19 de novembro de 2010): 985. http://dx.doi.org/10.1182/blood.v116.21.985.985.
Texto completo da fonteMarcelin, A. G., B. Visseaux, M. Wirden, L. Morand-Joubert, C. Soulie, C. Charpentier, B. Masquelier, D. Descamps e V. Calvez. "NRTI-sparing regimens yield higher rates of drug resistance than NRTI-based regimens for HIV-1 treatment". Journal of Global Antimicrobial Resistance 2, n.º 2 (junho de 2014): 103–6. http://dx.doi.org/10.1016/j.jgar.2013.12.001.
Texto completo da fonteDai, Yun, Shuang Chen, Xin-Yan Pei, Viswanathan Ramakrishnan, Michael Wang, Robert Orlowski, Paul Dent e Steven Grant. "Targeting CDK9 Dramatically Potentiates ABT-737-Induced Apoptosis in Human Multiple Myeloma Cells through a Bim-Dependent Mechanism." Blood 114, n.º 22 (20 de novembro de 2009): 297. http://dx.doi.org/10.1182/blood.v114.22.297.297.
Texto completo da fonteHoward, Caleigh, Shu Wiley, Wenzhao Dong, Andrea Mendiola, Veronica Partridge, Sara LeMar, Paul Amador et al. "Abstract 335: c-KIT targeted ETBs for cancer therapy and HSC transplant conditioning". Cancer Research 82, n.º 12_Supplement (15 de junho de 2022): 335. http://dx.doi.org/10.1158/1538-7445.am2022-335.
Texto completo da fontePuoti, Massimo, Alessandro Cozzi-Lepri, Fausto Ancarani, Raffaele Bruno, Silvia Ambu, Teresa Ferraro, Paolo Tundo et al. "The Management of Hepatitis B Virus/HIV-1 Co-Infected Patients Starting Their First Haart Regimen. Treating Two Infections for the Price of One Drug?" Antiviral Therapy 9, n.º 5 (julho de 2004): 811–17. http://dx.doi.org/10.1177/135965350400900506.
Texto completo da fonteTreon, Steven P., Kirsten Meid, Joshua Gustine, Christopher J. Patterson, Jeffrey V. Matous, Irene M. Ghobrial e Jorge J. Castillo. "Long-Term Outcome of a Prospective Study of Bortezomib, Dexamethasone and Rituximab (BDR) in Previously Untreated, Symptomatic Patients with Waldenstrom's Macroglobulinemia". Blood 126, n.º 23 (3 de dezembro de 2015): 1833. http://dx.doi.org/10.1182/blood.v126.23.1833.1833.
Texto completo da fonteYoshizawa, Toshio, Tomoko Yasuhiro, Hideyuki Honda e Kazuhito Kawabata. "ONO-4059—a Potent and Selective Reversible Bruton’s Tyrosine Kinase (Btk) Inhibitor: Single Agent, Twice Daily (BD) Dosing and Dosing with Food Results in Sustained, High Trough Levels of ONO-4059, Translating into 100% Tumour Remission in a TMD-8 Xenograft Model". Blood 124, n.º 21 (6 de dezembro de 2014): 4502. http://dx.doi.org/10.1182/blood.v124.21.4502.4502.
Texto completo da fonteWang, C., H. Song, Z. Yu e M. Quan. "AB1009 THE EFFICACY OF TOCILIZUMAB ON THE TREATMENT OF TAKAYASU ARTERITIS IN CHINESE CHILDREN". Annals of the Rheumatic Diseases 79, Suppl 1 (junho de 2020): 1798.2–1798. http://dx.doi.org/10.1136/annrheumdis-2020-eular.5778.
Texto completo da fonte